Understanding CONMED Corporation Business and Operations

CONMED Corporation is a leading medical technology company that provides a wide range of surgical and patient care solutions. Headquartered in Utica, New York, CONMED has been in business for over 60 years.

The company operates through three main segments: Surgical Systems, Ophthalmic Systems, and Sports Medicine. This diversified approach allows CONMED to cater to various medical specialties and provide innovative solutions.

CONMED's products and services include electrosurgical systems, orthopedic implants, and surgical instrumentation. These offerings enable medical professionals to perform complex procedures with precision and accuracy.

With a strong presence in over 100 countries, CONMED is committed to delivering high-quality products and services that improve patient outcomes and enhance the overall healthcare experience.

You might enjoy: Intuitive Surgical

CONMED Corporation offers a wide range of products and services for the medical industry.

The company provides orthopedic surgery products, including the BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors.

These products provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries.

CONMED's products also enable surgeons to perform minimally invasive sports medicine surgeries.

The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands.

In addition to orthopedic surgery products, CONMED offers general surgery products, including clinical insufflation systems under the AirSeal brand.

These products are used in minimally invasive surgeries and include smoke removal devices under the Buffalo Filter brand.

The company also provides endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors.

CONMED's electrosurgical solution comprises monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories.

The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors.

CONMED's products are used in various medical procedures, including gastroenterology procedures and surgeries such as orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries.

For your interest: PacifiCare Health Systems

CONMED Corporation's financial health is a crucial aspect to consider when evaluating its performance. The company's total cash stands at $33.94 million as of the most recent quarter.

The company's leverage is a notable aspect of its financial health, with a total debt/equity ratio of 87.93% as of the most recent quarter. This indicates a significant amount of debt relative to its equity.

Here's a breakdown of CONMED Corporation's key financial metrics:

The company's profitability is also worth noting, with a profit margin of 8.31% and a return on assets (ROA) of 4.03% as of the most recent trailing period.

Let's take a closer look at the financial statements of a company. The balance sheet and cash flow statement can give us a snapshot of the company's financial health. Total cash on hand is around $33.94 million.

The debt-to-equity ratio is a concern, standing at 87.93%. This means the company has a significant amount of debt compared to its equity. Levered free cash flow is $163.74 million, indicating the company has a decent amount of cash flow available.

Moving on to the income statement, we can see that the profit margin is 8.31%. This means the company is generating a decent amount of profit from its revenue. Revenue is a significant $1.33 billion, with net income available to common shareholders standing at $110.19 million.

Return on assets (ROA) is 4.03%, which is relatively low. Return on equity (ROE) is 11.69%, indicating the company is generating a decent return on its shareholders' equity. Diluted earnings per share (EPS) is $3.54, giving investors an idea of the company's profitability.

Here's a summary of the key financial metrics:

Understanding Valuation Measures is crucial for making informed investment decisions. Market capitalization, or Market Cap, is a key metric that stands at 1.44B.

Enterprise Value, a measure of a company's total value, is 2.29B. This is an important consideration when evaluating a company's worth.

The Trailing P/E ratio, a measure of how much investors are paying for each dollar of earnings, is 13.16. This ratio helps investors understand the relationship between a company's stock price and its earnings.

See what others are reading: Vf Corp Earnings

Forward P/E and PEG Ratio are not available for this company. We'll need to look at other metrics to get a complete picture.

Price/Sales, a measure of how much investors are paying for each dollar of sales, is 1.09. This ratio can be useful in comparing companies with different revenue streams.

Price/Book, a measure of how much investors are paying for each dollar of book value, is 1.44. This ratio can be useful in evaluating a company's asset utilization.

Here are the key valuation metrics for this company:

The US 2074101013 market is closed, but we can still take a look at its current status. The market closed at 04:00:02 pm EDT on 2025-10-24.

The 5-day change shows a decrease of -1.04% in the market. This change is a significant drop, but we'll need to keep an eye on it to see if it continues.

The 1st Jan Change shows a +6.23% increase, which is a notable improvement from the start of the year. However, it's essential to consider the -30.22% change from the beginning of the year to get a more comprehensive view.

Here's a breakdown of the changes:

CONMED CORP has an Investment Rating of BUY.

The target price for CONMED CORP is increasing over time, with the latest target price being $58.000000.

This target price is higher than the previous targets of $50.000000, $52.000000, and $53.000000.

The target price was $50.000000 5 days ago.

It was $52.000000 12 days ago.

The target price was $53.000000 19 days ago.

The Investment Rating of BUY has been consistent over the past few weeks.

Here's a summary of the target prices over the past month:

CONMED Corporation's Executive Committee consists of four key members: Patrick Beyer, Todd Garner, Richard Glaze, and Hollie Foust.

Patrick Beyer serves as the CEO, having taken on the role as of December 31, 2024. He is 59 years old.

Todd Garner has been the Director of Finance/CFO since January 1, 2018, and is 56 years old.

Richard Glaze, 59 years old, took on the role of Chief Tech/Sci/R&D Officer on October 31, 2023.

The ages of Hollie Foust and Kimberly Lockwood are not provided in the available information.

Here is a summary of the Executive Committee members:

The Executive Committee plays a crucial role in shaping the direction of CONMED Corporation. Led by Patrick Beyer, the CEO, the committee consists of four members, each bringing their expertise to the table.

Patrick Beyer, the CEO, has been at the helm since December 31, 2024. With 59 years of age, he brings a wealth of experience to the role.

Todd Garner, the Director of Finance/CFO, has been with the company since January 1, 2018, and has 56 years of age.

Richard Glaze, the Chief Technology/Science/R&D Officer, joined the company on October 31, 2023, and is also 59 years old.

Hollie Foust, the General Counsel, started her role on November 1, 2024, but her age is not publicly disclosed.

Kimberly Lockwood, the Comptroller/Controller/Auditor, began her tenure on September 29, 2024, but her age is also not publicly disclosed.

Here is a list of the Executive Committee members:

The composition of the Board of Directors for CONMED Corporation is an interesting aspect of the company's management and governance. The board is made up of seven members, each with their own unique background and experience.

You might enjoy: Joint Board for the Enrollment of Actuaries

LaVerne Council serves as the Chairman of the board, a position he has held since May 20, 2025. His leadership plays a crucial role in guiding the board's decisions.

The board members have a range of ages, from 46 to 73 years old. This diversity brings different perspectives and ideas to the table.

Here's a breakdown of the board members and their titles:

Each board member brings their own unique strengths and experiences to the table, contributing to the overall effectiveness of the board.

CONMED Corporation has seen significant growth in its sales over the years. Their sales have been steadily increasing, with a notable jump from $862M in 2020 to $1.24B in 2023.

The company's sales by activity have also been on the rise. In 2020, their sales for Development, Manufacturing and Sale of Surgical Devices and Related Equipment were $862M.

Here's a breakdown of CONMED Corporation's sales by activity over the past few years:

Their sales have consistently increased, with a notable jump from $1.05B in 2022 to $1.24B in 2023.